| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Name : Ibrutinib
Shape : White crystalline powder
Chronic lymphocytic leukemia, mantle cell lymphoma.
Ibrutinib, a targeted anticarcinogenesis drug developed by Johnson Johnson and Pharmacyclics Inc., was approved by the U.S. Food and Drug Administration (FDA) on November 13, 2013.The drug, marketed under the trade name Imbruvica, is used for the treatment of mantle cell lymphoma (MCL).
| Name | CAS | molecular | density |
| Ibrutinib | 936563-96-1 | C25H24N6O2 | 1.28 |
){kind=link}